View Future GrowthThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsApplied Genetic Technologies 過去の業績過去 基準チェック /06主要情報-39.78%収益成長率-21.13%EPS成長率Biotechs 業界の成長17.04%収益成長率-57.44%株主資本利益率-398.02%ネット・マージン-21,610.46%前回の決算情報30 Sep 2022最近の業績更新Reported Earnings • Sep 21Full year earnings released - US$2.17 loss per shareOver the last 12 months the company has reported total losses of US$45.9m, with losses widening by US$43.7m from the prior year.すべての更新を表示Recent updatesBoard Change • Oct 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Bill Aliski was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Price Target Changed • Sep 30Price target decreased to US$8.00Down from US$10.00, the current price target is an average from 5 analysts. New target price is 2,846% above last closing price of US$0.27. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$1.07 next year compared to a net loss per share of US$1.53 last year.Seeking Alpha • Jul 26AGTC receives positive feedback from FDA for manufacturing facilityApplied Genetic Technologies (NASDAQ:AGTC) said the U.S. Food and Drug Administration had provided favorable feedback on the current Good Manufacturing Practice (cGMP) design of AGTC’s manufacturing facility. The facility will support AGTC’s pipeline, including the late-stage development and potential commercialization of its eye diseases therapy like X-Linked Retinitis Pigmentosa (XLRP) and Achromatopsia B3 (ACHMB3) programs. The company said initial operations at the facility are expected to begin in Q4 with GMP capabilities expected to be finalized in Q1 2023. "We expect the facility will also play an important role in support of our promising pipeline of additional clinical and pre-clinical programs," the company said. (AGTC) rose 1.3% premarket.Seeking Alpha • Jul 12Applied Genetic Technologies proposes stock offering to fund clinical trialsApplied Genetic Technologies (NASDAQ:AGTC) announced Tuesday it plans to initiate underwritten stock offering that will see the issue of its common shares and accompanying stock purchase warrants. The company intends to use the net proceeds for fund its ongoing Skyline and Vista clinical trials in its X-linked retinitis pigmentosa program and its ongoing Phase 1/2 clinical trials in its Achromatopsia program, its preclinical development programs, investments in its manufacturing facility and for working capital and other general corporate purposes, including scheduled payments under its term loan with Hercules Capital, Inc. AGTC Shares fell 29% after-hours, Tuesday, to trade at $0.60. Earlier: Applied Genetic Technologies raised $9.8M in stock offeringPrice Target Changed • Jun 10Price target decreased to US$10.57Down from US$14.63, the current price target is an average from 7 analysts. New target price is 1,037% above last closing price of US$0.93. Stock is down 78% over the past year. The company is forecast to post a net loss per share of US$1.47 next year compared to a net loss per share of US$1.77 last year.Price Target Changed • May 17Price target decreased to US$14.13Down from US$15.63, the current price target is an average from 7 analysts. New target price is 1,586% above last closing price of US$0.84. Stock is down 81% over the past year. The company is forecast to post a net loss per share of US$1.66 next year compared to a net loss per share of US$1.77 last year.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Bill Aliski was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Seeking Alpha • Jan 12Applied Genetic Tech: A Speculative Biotech With Potential To Turn Corner In 2022AGTC-501 is being developed to treat patients with X-linked retinitis pigmentosa. Two near-term results are expected in Q2 and Q3 of 2022, respectively; they are 3-month results from the SKYLINE study and 24-month results from the phase 1/2 study using AGTC-501. Results from two phase 1/2 studies pediatric patients with Achromatopsia are expected in Q1 of 2022. Applied Genetic Technologies Corporation had $90.5 million cash as of September 30, 2021; enough cash to fund its operations into 2023.Seeking Alpha • Dec 14An Assessment Of Applied Genetic Technologies CorporationIn the spotlight today is a developmental concern called Applied Genetic Technologies Corporation. The company has several gene therapy candidates in its pipeline and numerous potential milestones in 2022. A full investment analysis is provided in the paragraphs below.Board Change • Nov 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Bill Aliski was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Oct 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Bill Aliski was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Seeking Alpha • Jul 15Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased RiskApplied Genetic Technologies Corporation is a mid-clinical-stage biotechnology company developing genetic therapies for rare and debilitating diseases. AGTC's initial focus is on ophthalmology (study of medical conditions relating to the eye) where AGTC has active programs for X-linked retinitis pigmentosa, achromatopsia, and optogenetics. AGT Corporation is in a reasonable financial position evidenced by 2+ years of cash runway driven by a low-cash burn (TTM: -$53M) and cash of $111M (March 2021). XLRP is being targeted by AGTC's lead therapeutic, RPGR, currently in a Phase 2/3 Vista study (data expected: 3Q 22) and a Phase 1/2 expansion trial known as Skyline (data expected: 4Q 21). In summary, the author projects Applied Genetic Technologies Corporation as a high-risk "hold".分析記事 • May 21Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyst Estimate Surprise Post Earnings • Feb 12Earnings beat expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.0%.分析記事 • Feb 05What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?Every investor in Applied Genetic Technologies Corporation ( NASDAQ:AGTC ) should be aware of the most powerful...Price Target Changed • Feb 02Price target lowered to US$11.44Down from US$14.81, the current price target is an average from 6 analysts. The new target price is 190% above the current share price of US$3.95. As of last close, the stock is down 35% over the past year.Is New 90 Day High Low • Jan 29New 90-day low: US$3.95The company is down 23% from its price of US$5.16 on 30 October 2020. The American market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 24% over the same period.分析記事 • Jan 06Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Dec 11What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see...Is New 90 Day High Low • Nov 18New 90-day low: US$4.33The company is down 21% from its price of US$5.51 on 20 August 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Analyst Estimate Surprise Post Earnings • Nov 18Earnings beat expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 13%. Over the next year, revenue is expected to shrink by 88% compared to a 365% growth forecast for the Biotechs industry in the US.Reported Earnings • Sep 21Full year earnings released - US$2.17 loss per shareOver the last 12 months the company has reported total losses of US$45.9m, with losses widening by US$43.7m from the prior year.収支内訳Applied Genetic Technologies の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqGM:AGTC 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費30 Sep 220-70172830 Jun 220-69172831 Mar 221-63172531 Dec 211-63162330 Sep 211-60152230 Jun 211-58152131 Mar 210-60142131 Dec 200-57142130 Sep 202-50142730 Jun 202-46142131 Mar 203-42132131 Dec 1924-19132930 Sep 1928-15132030 Jun 1942-2131931 Mar 1947213231 Dec 1829-1814130 Sep 1828-1914530 Jun 1824-2114031 Mar 1827-18142731 Dec 1732-11131530 Sep 1738-4121530 Jun 17390111531 Mar 17436111131 Dec 164710101130 Sep 164811101130 Jun 1647-1101131 Mar 1636-1210031 Dec 1524-20110質の高い収益: AGTCは現在利益が出ていません。利益率の向上: AGTCは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: AGTCは利益が出ておらず、過去 5 年間で損失は年間39.8%の割合で増加しています。成長の加速: AGTCの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: AGTCは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。株主資本利益率高いROE: AGTCは現在利益が出ていないため、自己資本利益率 ( -398.02% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2022/12/01 13:06終値2022/11/30 00:00収益2022/09/30年間収益2022/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Applied Genetic Technologies Corporation 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関James BirchenoughBMO Capital Markets Equity ResearchYun ZhongBrean Capital Historical (Janney Montgomery)Yun ZhongBTIG7 その他のアナリストを表示
Reported Earnings • Sep 21Full year earnings released - US$2.17 loss per shareOver the last 12 months the company has reported total losses of US$45.9m, with losses widening by US$43.7m from the prior year.
Board Change • Oct 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Bill Aliski was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Price Target Changed • Sep 30Price target decreased to US$8.00Down from US$10.00, the current price target is an average from 5 analysts. New target price is 2,846% above last closing price of US$0.27. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$1.07 next year compared to a net loss per share of US$1.53 last year.
Seeking Alpha • Jul 26AGTC receives positive feedback from FDA for manufacturing facilityApplied Genetic Technologies (NASDAQ:AGTC) said the U.S. Food and Drug Administration had provided favorable feedback on the current Good Manufacturing Practice (cGMP) design of AGTC’s manufacturing facility. The facility will support AGTC’s pipeline, including the late-stage development and potential commercialization of its eye diseases therapy like X-Linked Retinitis Pigmentosa (XLRP) and Achromatopsia B3 (ACHMB3) programs. The company said initial operations at the facility are expected to begin in Q4 with GMP capabilities expected to be finalized in Q1 2023. "We expect the facility will also play an important role in support of our promising pipeline of additional clinical and pre-clinical programs," the company said. (AGTC) rose 1.3% premarket.
Seeking Alpha • Jul 12Applied Genetic Technologies proposes stock offering to fund clinical trialsApplied Genetic Technologies (NASDAQ:AGTC) announced Tuesday it plans to initiate underwritten stock offering that will see the issue of its common shares and accompanying stock purchase warrants. The company intends to use the net proceeds for fund its ongoing Skyline and Vista clinical trials in its X-linked retinitis pigmentosa program and its ongoing Phase 1/2 clinical trials in its Achromatopsia program, its preclinical development programs, investments in its manufacturing facility and for working capital and other general corporate purposes, including scheduled payments under its term loan with Hercules Capital, Inc. AGTC Shares fell 29% after-hours, Tuesday, to trade at $0.60. Earlier: Applied Genetic Technologies raised $9.8M in stock offering
Price Target Changed • Jun 10Price target decreased to US$10.57Down from US$14.63, the current price target is an average from 7 analysts. New target price is 1,037% above last closing price of US$0.93. Stock is down 78% over the past year. The company is forecast to post a net loss per share of US$1.47 next year compared to a net loss per share of US$1.77 last year.
Price Target Changed • May 17Price target decreased to US$14.13Down from US$15.63, the current price target is an average from 7 analysts. New target price is 1,586% above last closing price of US$0.84. Stock is down 81% over the past year. The company is forecast to post a net loss per share of US$1.66 next year compared to a net loss per share of US$1.77 last year.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Bill Aliski was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Seeking Alpha • Jan 12Applied Genetic Tech: A Speculative Biotech With Potential To Turn Corner In 2022AGTC-501 is being developed to treat patients with X-linked retinitis pigmentosa. Two near-term results are expected in Q2 and Q3 of 2022, respectively; they are 3-month results from the SKYLINE study and 24-month results from the phase 1/2 study using AGTC-501. Results from two phase 1/2 studies pediatric patients with Achromatopsia are expected in Q1 of 2022. Applied Genetic Technologies Corporation had $90.5 million cash as of September 30, 2021; enough cash to fund its operations into 2023.
Seeking Alpha • Dec 14An Assessment Of Applied Genetic Technologies CorporationIn the spotlight today is a developmental concern called Applied Genetic Technologies Corporation. The company has several gene therapy candidates in its pipeline and numerous potential milestones in 2022. A full investment analysis is provided in the paragraphs below.
Board Change • Nov 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Bill Aliski was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Oct 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Bill Aliski was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Seeking Alpha • Jul 15Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased RiskApplied Genetic Technologies Corporation is a mid-clinical-stage biotechnology company developing genetic therapies for rare and debilitating diseases. AGTC's initial focus is on ophthalmology (study of medical conditions relating to the eye) where AGTC has active programs for X-linked retinitis pigmentosa, achromatopsia, and optogenetics. AGT Corporation is in a reasonable financial position evidenced by 2+ years of cash runway driven by a low-cash burn (TTM: -$53M) and cash of $111M (March 2021). XLRP is being targeted by AGTC's lead therapeutic, RPGR, currently in a Phase 2/3 Vista study (data expected: 3Q 22) and a Phase 1/2 expansion trial known as Skyline (data expected: 4Q 21). In summary, the author projects Applied Genetic Technologies Corporation as a high-risk "hold".
分析記事 • May 21Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analyst Estimate Surprise Post Earnings • Feb 12Earnings beat expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.0%.
分析記事 • Feb 05What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?Every investor in Applied Genetic Technologies Corporation ( NASDAQ:AGTC ) should be aware of the most powerful...
Price Target Changed • Feb 02Price target lowered to US$11.44Down from US$14.81, the current price target is an average from 6 analysts. The new target price is 190% above the current share price of US$3.95. As of last close, the stock is down 35% over the past year.
Is New 90 Day High Low • Jan 29New 90-day low: US$3.95The company is down 23% from its price of US$5.16 on 30 October 2020. The American market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 24% over the same period.
分析記事 • Jan 06Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Dec 11What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see...
Is New 90 Day High Low • Nov 18New 90-day low: US$4.33The company is down 21% from its price of US$5.51 on 20 August 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Analyst Estimate Surprise Post Earnings • Nov 18Earnings beat expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 13%. Over the next year, revenue is expected to shrink by 88% compared to a 365% growth forecast for the Biotechs industry in the US.
Reported Earnings • Sep 21Full year earnings released - US$2.17 loss per shareOver the last 12 months the company has reported total losses of US$45.9m, with losses widening by US$43.7m from the prior year.